Liquid Biopsy Market by Product (Assay Kits, Instruments, Service), Circulating Biomarkers (CTC, ctDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast, Prostate), Non-Cancer), End User (Reference Lab, Hospitals) - Global Forecast to 2026
[231 Pages Report] The global liquid biopsy market is projected to reach USD 5.8 billion by 2026 from USD 2.5 billion in 2021, at a CAGR of 18.1% during the forecast period. Market is driven by the rising incidence and prevalence of cancer and the increasing preference for noninvasive treatment procedures.
To know about the assumptions considered for the study, Request for Free Sample Report
OVID-19 Impact on Global Liquid Biopsy Market
The unprecedented impact of COVID-19 has been far-reaching, but the effects on cancer patients make them one of the worst affected groups. COVID-19 has profoundly impacted the number of patients undergoing cancer screening, diagnosis, and treatment. The increased pressure due to the growing rate of COVID-19 patients' hospitalization led to the re-profiling of many hospitals and departments, including oncology clinics for treating patients with the COVID-19. Consequently, according to one study, many diagnostic and treatment procedures had been canceled or postponed around the world, including as many as 2.3 million cancer surgeries.
However, a resurgence in testing numbers is seen as countries gradually ease restrictions on movement. With the COVID-19 pandemic, responding to growing cancer incidence has become a pressing medical issue worldwide. Several patients affected with COVID-19 were people with malignancies, due to which cancer has been identified as a risk factor for COVID-19. Research in this area is further undertaken to better understand the infection dynamics, which is expected to propel the cancer research field further. This is further expected to drive the demand for liquid biopsy products.
Market Dynamics
Driver: Rising incidence and prevalence of cancer
Globally, there has been a significant increase in the number of people who have cancer. The rising prevalence of cancer can be attributed to several factors, such as environmental factors, tobacco consumption, infectious agents such as Hepatitis B and C, and lifestyle changes. According to the WHO, cancer is the second-leading cause of death globally. International Agency for Research on Cancer (IARC) estimated the global cancer burden, indicating that it has risen to 19.3 million cases and 9.96 million cancer deaths in 2020. Liquid biopsy holds several benefits over traditional cancer diagnostics techniques—reduced cost, early prognosis, therapy monitoring, detection of tumor heterogeneity, acquired drug resistance, and patient comfort (by eliminating the need for surgery). As a result, the preference for liquid biopsy will likely rise in the forecast period, proportional to the growth in cancer prevalence.
Restraint: The lower sensitivity of certain liquid biopsies
Detecting ctDNA in liquid biopsies is technically challenging because the levels of ctDNA of any given cancer mutation may be very low in the plasma of a cancer patient, especially after treatment or surgery. The sampling statistics mean that in any individual sample of plasma from a patient, there may be less than one detectable copy of the ctDNA with the cancer mutation. This may result in the ctDNA not being detected in the patient sample, even though it is present in the plasma, but at a low level. This leads to false-negative results in which ctDNA is not detected even though it is present and impacts the informative value of the liquid biopsy tests for cancer. In some cases, false negatives may mean that the recurrence of a tumor is not detected at an early stage.
Opportunity: The growing significance of companion diagnostics
Companion diagnostics include tests or assays intended to assist healthcare providers in making treatment decisions for patients based on the best response to therapy. The co-development of companion diagnostics with therapeutic products can significantly alter the drug development process and commercialize drug candidates by yielding safer drugs with enhanced therapeutic efficacy quickly and cost-effectively. With the increased demand for high-priced specialist therapies and safer drugs, the market for companion diagnostics has high growth potential. The growing importance of companion diagnostics is also providing growth opportunities for the liquid biopsy market.
Challenge: Unclear reimbursement scenario
The process of paying for expensive molecular tests and the expertise of the multiple professionals required to interpret test results and formulate treatment plans are inconsistent and complex. This is especially an issue with newer technologies such as liquid biopsy, with higher price tags. Physicians, pathologists, and patients often do not know the costs of molecular testing services until they are reimbursed or billed. The confusion is distressing for both patients and providers.
Payers also structure their policies for biomarker coverage in multiple ways, making them difficult to understand. While some reimburse for many types of tests, others reimburse for only the most basic tests or specific clinical conditions and genes. This wide variation often increases the challenge of assessing and tracking numerous coverage policies.
“In 2020, assay kits segment accounted for the largest share of the liquid biopsy market, by product & service”
The liquid biopsy market is segmented into assay kits, instruments, and services based on product & service. The assay kits segment accounted for the largest share of the market in 2020. The standard purchase requirement of assay kits makes them a recurrent cost which is a key factor attributing to the growth of this segment.
“In 2020, cancer application segment accounted for the largest share in the market, by application”
The liquid biopsy market is segmented into cancer and non-cancer applications based on application. The cancer application segment accounted for the largest share of the market in 2020. Factors such as the increasing prevalence of cancer and the growing number of research studies on liquid biopsy for cancer applications are driving the growth of this segment.
“In 2020, reference laboratories segment accounted for the largest share in the market, by end user”
The liquid biopsy market has been segmented into reference laboratories, hospitals and physician laboratories, academic & research centers, and other end users. The reference laboratories segment accounted for the largest share of the market in 2020. The increasing outsourcing of liquid biopsy tests to reference laboratories is driving the growth of this segment.
“North America is the largest regional market for liquid biopsy”
The global liquid biopsy market has been segmented into four major regions—North America, Europe, the Asia Pacific, and the Rest of the World. In 2020, North America accounted for the largest share of the market. The large share of this regional segment can be attributed to the easy accessibility to technologically advanced instruments, highly developed healthcare systems in the US and Canada, and presence of many leading national clinical laboratories.
To know about the assumptions considered for the study, download the pdf brochure
Some Key Players in the Liquid Biopsy Market (2021- 2026)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Myriad Genetics, Inc. (US)
- QIAGEN N.V. (Netherlands)
- Thermo Fisher Scientific, Inc. (US)
- Guardant Health, Inc. (US)
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
2019–2026 |
|
Base year considered |
2020 |
|
Forecast period |
2021–2026 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Product & service, circulating biomarkers, technology, application, clinical application, end user, and region |
|
Geographies covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Companies covered |
F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics, Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), Guardant Health, Inc. (US), MDxHealth SA (Belgium), Exact Sciences Corporation (US), Illumina Inc. (US), Sysmex Inostics (US), Bio-Rad Laboratories, Inc. (US), Biocept, Inc. (US), NeoGenomics, Inc. (US), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences, Inc. (US), Exosome Diagnostics, Inc. (US), Agena Bioscience, Inc. (US), MedGenome Inc. (US), Epigenomics AG (Germany), and Personal Genome Diagnostics, Inc. (US). |
This report categorizes the liquid biopsy market into the following segments and subsegments:
By Product & Service
- Assay Kits
- Instruments
- Services
By Circulating Biomarkers
- Circulating Tumor Cells
- Circulating Tumor DNA (ctDNA)
- Cell-free DNA (cfDNA)
- Extracellular Vesicles (EVS)
- Other Circulating Biomarkers
By Application
- Cancer Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Other Cancers
- Non-cancer Applications
By Technology
- Multi-gene Parallel Analysis using NGS
- Single-gene Analysis using PCR Microarrays
By Clinical Application
- Early Cancer Screening
- Therapy Selection
- Treatment Monitoring
- Recurrence Monitoring
By End User
- Reference Laboratories
- Hospitals and Physician Laboratories
- Academic & Research Centers
- Other End Users
By Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Rest of the World
Recent Developments
- In June 2021, Guardant Health, Inc. (US) launched its Guardant360 Response test that detects changes in circulating tumor DNA (ctDNA) levels.
- In October 2020, F. Hoffmann-La Roche Ltd. (Switzerland) received the US FDA approval of expanded claims for the cobas EGFR Mutation Test v2 to be used as a companion diagnostic (CDx) for a broader group of therapies to treat non-small cell lung cancer (NSCLC).
- In March 2020, Biocept, Inc. (US) entered into an agreement with a second California-based independent physician association (IPA) to provide its Target Selector liquid biopsy assay services to physicians and patients in the network.
Frequently Asked Questions (FAQ):
What are the recent trends affecting the liquid biopsy market?
Recent trends affecting the liquid biopsy market are the COVID-19 outbreak, rising incidence and prevalence of cancer, cancer awareness initiatives undertaken by global health organizations, and the increasing preference for noninvasive procedures
What are the major application areas of liquid biopsy?
Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications. In 2020, the cancer application segment accounted for the largest share of the liquid biopsy market. The large share of this segment can be mainly attributed to factors such as the increasing prevalence of cancer and the growing number of research studies on liquid biopsy for cancer applications.
Who are the key players in the liquid biopsy market?
The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Myriad Genetics, Inc. (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), Guardant Health, Inc. (US), MDxHealth SA (Belgium), Exact Sciences Corporation (US), Illumina Inc. (US), Sysmex Inostics (US), Bio-Rad Laboratories, Inc. (US), Biocept, Inc. (US), NeoGenomics, Inc. (US), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences, Inc. (US), Exosome Diagnostics, Inc. (US), Agena Bioscience, Inc. (US), MedGenome Inc. (US), Epigenomics AG (Germany), and Personal Genome Diagnostics, Inc. (US).
Who are the major end users of liquid biopsy products & services?
Based on end user, the liquid biopsy market has been segmented into reference laboratories, hospitals and physician laboratories, academic & research centers, and other end users. In 2020, the reference laboratories segment accounted for the largest share of the liquid biopsy market and was expected to grow at the highest CAGR during the forecast period. The large share of the reference laboratories segment can be attributed to the increasing outsourcing of liquid biopsy tests to reference laboratories.
Which region is lucrative for the liquid biopsy market?
Like China, Japan, and India, the emerging economies in the Asia Pacific region will be the lucrative markets for liquid biopsy. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 29)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.2.2 MARKETS COVERED
FIGURE 1 LIQUID BIOPSY MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 35)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 2 LIQUID BIOPSY MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (LIQUID BIOPSY MARKET)
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast (2021-2026)
2.3.1.4 CAGR projections
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 7 LIQUID BIOPSY MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 ASSUMPTIONS FOR THE STUDY
2.7 LIMITATIONS
2.8 RISK ASSESSMENT
2.8.1 RISK ASSESSMENT: LIQUID BIOPSY MARKET
2.9 GROWTH RATE ASSUMPTIONS
2.10 COVID-19 HEALTH ASSESSMENT
2.11 COVID-19 ECONOMIC ASSESSMENT
2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
2.13 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE LIQUID BIOPSY MARKET
3 EXECUTIVE SUMMARY (Page No. - 51)
FIGURE 11 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
FIGURE 12 GLOBAL MARKET, BY CIRCULATING BIOMARKERS, 2021 VS. 2026 (USD MILLION)
FIGURE 13 GLOBAL MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 14 GLOBAL MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 15 GLOBAL MARKET, BY CLINICAL APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 16 GLOBAL MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 17 GLOBAL MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 56)
4.1 LIQUID BIOPSY MARKET OVERVIEW
FIGURE 18 THE RISING INCIDENCE OF CANCER IS DRIVING THE GROWTH OF THE GLOBAL MARKET
4.2 GLOBAL MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
FIGURE 19 THE ASSAY KITS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.3 GLOBAL MARKET SHARE, BY CIRCULATING BIOMARKERS, 2021 VS. 2026
FIGURE 20 THE CIRCULATING TUMOR CELLS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.4 GLOBAL MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
FIGURE 21 MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
4.5 LIQUID BIOPSY MARKET SHARE, BY APPLICATION, 2021 VS. 2026
FIGURE 22 CANCER APPLICATIONS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
4.6 GLOBAL MARKET SHARE, BY CLINICAL APPLICATION, 2021 VS. 2026
FIGURE 23 THERAPY SELECTION SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
4.7 LIQUID BIOPSY MARKET SHARE, BY END USER, 2021 VS. 2026
FIGURE 24 REFERENCE LABORATORIES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
4.8 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 25 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE GLOBAL MARKET DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 61)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 26 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence and prevalence of cancer
TABLE 1 NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020, BY TYPE OF CANCER
5.2.1.2 Cancer awareness initiatives undertaken by global health organizations
5.2.1.3 Increasing preference for noninvasive treatment procedures
5.2.2 RESTRAINTS
5.2.2.1 The lower sensitivity of certain liquid biopsies
5.2.3 OPPORTUNITIES
5.2.3.1 The growing significance of companion diagnostics
5.2.3.2 Growth opportunities in emerging countries
5.2.4 CHALLENGES
5.2.4.1 Unclear reimbursement scenario
5.3 IMPACT OF COVID-19 ON THE LIQUID BIOPSY MARKET
5.4 REALISTIC, PESSIMISTIC, AND OPTIMISTIC SCENARIOS
5.4.1 GLOBAL MARKET
FIGURE 27 REALISTIC SCENARIO
FIGURE 28 PESSIMISTIC SCENARIO
FIGURE 29 OPTIMISTIC SCENARIO
5.5 PRICING ANALYSIS
TABLE 2 PRICE OF LIQUID BIOPSY PRODUCTS (2021)
5.6 PATENT ANALYSIS
5.6.1 PATENT ANALYSIS OF CIRCULATING BIOMARKERS
5.7 VALUE CHAIN ANALYSIS
FIGURE 30 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE
FIGURE 31 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
5.8 ECOSYSTEM ANALYSIS OF THE LIQUID BIOPSY MARKET
FIGURE 32 GLOBAL MARKET: ECOSYSTEM ANALYSIS
5.9 PORTER’S FIVE FORCES ANALYSIS
TABLE 3 GLOBAL MARKET: PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 DEGREE OF COMPETITION
5.10 REGULATORY LANDSCAPE
5.10.1 NORTH AMERICA
5.10.1.1 US
5.10.1.2 Canada
5.10.2 EUROPE
5.10.3 ASIA PACIFIC
5.10.3.1 China
5.10.3.2 Japan
5.10.4 LATIN AMERICA
5.10.4.1 Brazil
5.10.4.2 Mexico
5.10.5 MIDDLE EAST
5.10.6 AFRICA
5.11 TECHNOLOGY ANALYSIS
5.12 PESTLE ANALYSIS
5.13 TRADE ANALYSIS
5.13.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
5.13.1.1 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (USD Million)
5.13.1.2 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (Tons)
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR LIQUID BIOPSY PRODUCT MANUFACTURERS
5.14.2 REVENUE SHIFT FOR THE LIQUID BIOPSY MARKET
6 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE (Page No. - 81)
6.1 INTRODUCTION
TABLE 4 GLOBAL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
6.2 ASSAY KITS
6.2.1 REPEATED REQUIREMENT PURCHASES OF ASSAY KITS TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 5 KEY PRODUCTS IN THE ASSAY KITS MARKET
TABLE 6 GLOBAL MARKET FOR ASSAY KITS, BY REGION, 2019–2026 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 LATEST ADVANCEMENTS IN PCR TECHNOLOGIES TO ENSURE MARKET GROWTH OF THIS SEGMENT
TABLE 7 KEY PRODUCTS IN THE INSTRUMENTS MARKET
TABLE 8 GLOBAL MARKET FOR INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.4 SERVICES
6.4.1 INCREASING NUMBER OF LIQUID BIOPSY-BASED SERVICE DEVELOPMENTS TO SUPPORT THE MARKET GROWTH
TABLE 9 GLOBAL MARKET FOR SERVICES, BY REGION, 2019–2026 (USD MILLION)
7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS (Page No. - 87)
7.1 INTRODUCTION
7.1.1 PRIMARY NOTES
7.1.1.1 Key industry insights
TABLE 10 GLOBAL MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
7.2 CIRCULATING TUMOR CELLS (CTC)
7.2.1 BENEFITS OF EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF THE OVERALL TUMOR BURDEN TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 11 GLOBAL MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2019–2026 (USD MILLION)
7.3 CIRCULATING TUMOR DNA (CTDNA)
7.3.1 CTDNA ANALYSIS CAN SIGNIFICANTLY IMPROVE TUMOR DIAGNOSIS, THUS LEADING TO EARLY-STAGE DETECTION OF CANCER
TABLE 12 GLOBAL MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2019–2026 (USD MILLION)
7.4 CELL-FREE DNA (CFDNA)
7.4.1 APPLICATION OF CFDNA IN PRENATAL SCREENING IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 13 LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION, 2019–2026 (USD MILLION)
7.5 EXTRACELLULAR VESICLES (EVS)
7.5.1 EVS ARE STABLE IN BLOOD CIRCULATION OVER OTHER ANALYTES, THUS ENSURING THE GROWTH OF THIS SEGMENT
TABLE 14 GLOBAL MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2019–2026 (USD MILLION)
7.6 OTHER CIRCULATING BIOMARKERS
TABLE 15 GLOBAL MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2019–2026 (USD MILLION)
8 LIQUID BIOPSY MARKET, BY TECHNOLOGY (Page No. - 94)
8.1 INTRODUCTION
8.1.1 PRIMARY NOTES
8.1.1.1 Key industry insights
TABLE 16 GLOBAL MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS
8.2.1 HIGH SENSITIVITY AND ECONOMIC BENEFITS TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 17 GLOBAL MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, 2019–2026 (USD MILLION)
8.3 SINGLE-GENE ANALYSIS USING PCR MICROARRAYS
8.3.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 18 GLOBAL MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, 2019–2026 (USD MILLION)
9 LIQUID BIOPSY MARKET, BY APPLICATION (Page No. - 97)
9.1 INTRODUCTION
TABLE 19 GLOBAL MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
9.2 CANCER APPLICATIONS
TABLE 20 CANCER INCIDENCE, BY REGION, 2020 VS. 2040 (MILLION)
TABLE 21 GLOBAL MARKET FOR CANCER APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 22 GLOBAL MARKET FOR CANCER APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
9.2.1 LUNG CANCER
9.2.1.1 Increasing prevalence of lung cancer to propel the market growth
TABLE 23 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 24 GLOBAL MARKET FOR LUNG CANCER, BY REGION, 2019–2026 (USD MILLION)
9.2.2 BREAST CANCER
9.2.2.1 Increasing government funding for breast cancer research is expected to drive the market growth
TABLE 25 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 26 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION, 2019–2026 (USD MILLION)
9.2.3 COLORECTAL CANCER
9.2.3.1 Increasing prevalence of colorectal cancer to propel the market growth
TABLE 27 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 28 GLOBAL MARKET FOR COLORECTAL CANCER, BY REGION, 2019–2026 (USD MILLION)
9.2.4 PROSTATE CANCER
9.2.4.1 Growing number of prostate cancer patients to drive the growth of this market
TABLE 29 PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 30 GLOBAL MARKET FOR PROSTATE CANCER, BY REGION, 2019–2026 (USD MILLION)
9.2.5 MELANOMA
9.2.5.1 Increasing need for the early diagnosis of genetically mutated tumors to drive market growth
TABLE 31 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 32 MARKET FOR MELANOMA, BY REGION, 2019–2026 (USD MILLION)
9.2.6 OTHER CANCERS
TABLE 33 GLOBAL CANCER INCIDENCE, 2020
TABLE 34 MARKET FOR OTHER CANCERS, BY REGION, 2019–2026 (USD MILLION)
9.3 NON-CANCER APPLICATIONS
9.3.1 APPLICATIONS OF LIQUID BIOPSY FOR NIPT AND ORGAN TRANSPLANTATION DIAGNOSIS DRIVES THE GROWTH OF THIS SEGMENT
TABLE 35 MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
10 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION (Page No. - 110)
10.1 INTRODUCTION
TABLE 36 MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
10.2 THERAPY SELECTION
10.2.1 INCREASING PREFERENCE DUE TO NONINVASIVENESS OF LIQUID BIOPSY TESTS TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 37 MARKET FOR THERAPY SELECTION, BY REGION, 2019–2026 (USD MILLION)
10.3 TREATMENT MONITORING
10.3.1 LIQUID BIOPSY FOR TREATMENT MONITORING QUANTITATIVELY CALCULATES THE CONCENTRATION OF CANCER-RELATED MUTATIONS
TABLE 38 MARKET FOR TREATMENT MONITORING, BY REGION, 2019–2026 (USD MILLION)
10.4 RECURRENCE MONITORING
10.4.1 THE ABILITY TO DETECT CANCER MUTATION THROUGH CTDNA IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 39 MARKET FOR RECURRENCE MONITORING, BY REGION, 2019–2026 (USD MILLION)
10.5 EARLY CANCER SCREENING
10.5.1 POTENTIAL OF LIQUID BIOPSY IN THE DETECTION OF CANCER AT EARLY STAGES TO DRIVE MARKET GROWTH
TABLE 40 MARKET FOR EARLY CANCER SCREENING, BY REGION, 2019–2026 (USD MILLION)
11 LIQUID BIOPSY MARKET, BY END USER (Page No. - 116)
11.1 INTRODUCTION
TABLE 41 MARKET, BY END USER, 2019–2026 (USD MILLION)
11.2 REFERENCE LABORATORIES
11.2.1 INCREASING OUTSOURCING OF LIQUID BIOPSY TESTS TO REFERENCE LABORATORIES DRIVES THE GROWTH OF THIS SEGMENT
TABLE 42 MARKET FOR REFERENCE LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
11.3 HOSPITALS AND PHYSICIAN LABORATORIES
11.3.1 THE INCREASING NUMBER OF HOSPITALS WORLDWIDE IS A MAJOR FACTOR DRIVING THE GROWTH OF THIS SEGMENT
TABLE 43 MARKET FOR HOSPITALS AND PHYSICIAN LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
11.4 ACADEMIC & RESEARCH CENTERS
11.4.1 GROWING FOCUS OF RESEARCH IN THE DEVELOPMENT OF INNOVATIVE LIQUID BIOPSY TESTS TO DRIVE THE GROWTH OF THIS END-USER SEGMENT
TABLE 44 GLOBAL MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2019–2026 (USD MILLION)
11.5 OTHER END USERS
TABLE 45 GLOBAL MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)
12 LIQUID BIOPSY MARKET, BY REGION (Page No. - 121)
12.1 INTRODUCTION
TABLE 46 GLOBAL MARKET, BY REGION, 2019–2026 (USD MILLION)
12.2 NORTH AMERICA
TABLE 47 NUMBER OF NEW CANCER CASES IN NORTH AMERICA IN 2020, BY TYPE OF CANCER
FIGURE 33 NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT
TABLE 48 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 49 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 50 NORTH AMERICA: MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
TABLE 51 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 52 NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 53 NORTH AMERICA: MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
TABLE 54 NORTH AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
12.2.1 US
12.2.1.1 The increasing prevalence of cancer is a key factor expected to drive market growth in the US
TABLE 55 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 56 US: MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
TABLE 57 US: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 58 US: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 59 US: MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
TABLE 60 US: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.2.2 CANADA
12.2.2.1 The availability of various cancer screening programs in Canada is expected to drive market growth in Canada
TABLE 61 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 62 CANADA: MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
TABLE 63 CANADA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 64 CANADA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 65 CANADA: MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
TABLE 66 CANADA: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.3 EUROPE
TABLE 67 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 68 EUROPE: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 69 EUROPE: MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
TABLE 70 EUROPE: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 71 EUROPE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 72 EUROPE: MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
TABLE 73 EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.3.1 GERMANY
12.3.1.1 Increasing healthcare expenditure to drive the market growth in Germany
TABLE 74 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 75 GERMANY: MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
TABLE 76 GERMANY: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 77 GERMANY: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 78 GERMANY: MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
TABLE 79 GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.3.2 UK
12.3.2.1 Increasing number of diagnostic laboratories in the UK to propel the market growth
TABLE 80 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 81 UK: MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
TABLE 82 UK: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 83 UK: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 84 UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
TABLE 85 UK: MARKET, BY END USER, 2019–2026 (USD MILLION)
12.3.3 FRANCE
12.3.3.1 Rising R&D expenditure in France to drive the market growth
TABLE 86 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 87 FRANCE: MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
TABLE 88 FRANCE: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 89 FRANCE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 90 FRANCE: MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
TABLE 91 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.3.4 REST OF EUROPE
TABLE 92 ROE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 93 ROE: MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
TABLE 94 ROE: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 95 ROE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 96 ROE: MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
TABLE 97 ROE: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.4 ASIA PACIFIC
FIGURE 34 APAC: LIQUID BIOPSY MARKET SNAPSHOT
TABLE 98 APAC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 99 APAC: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 100 APAC: MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
TABLE 101 APAC: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 102 APAC: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 103 APAC: MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
TABLE 104 APAC: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.4.1 CHINA
12.4.1.1 Growing public access to advanced healthcare facilities to drive the market growth in China
TABLE 105 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 106 CHINA: MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
TABLE 107 CHINA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 108 CHINA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 109 CHINA: MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
TABLE 110 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.4.2 JAPAN
12.4.2.1 Universal healthcare reimbursement policy to drive the market growth in Japan
TABLE 111 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 112 JAPAN: MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
TABLE 113 JAPAN: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 114 JAPAN: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 115 JAPAN: MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
TABLE 116 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.4.3 INDIA
12.4.3.1 Increasing private & public investments in the country’s healthcare system is expected to drive the market growth
TABLE 117 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 118 INDIA: MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
TABLE 119 INDIA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 120 INDIA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 121 INDIA: MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
TABLE 122 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.4.4 REST OF ASIA PACIFIC
TABLE 123 ROAPAC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 124 ROAPAC: MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
TABLE 125 ROAPAC: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 126 ROAPAC: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 127 ROAPAC: MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
TABLE 128 ROAPAC: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION)
12.5 REST OF THE WORLD
TABLE 129 ROW: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 130 ROW: MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION)
TABLE 131 ROW: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 132 ROW: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 133 ROW: MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION)
TABLE 134 ROW: MARKET, BY END USER, 2019–2026 (USD MILLION)
13 COMPETITIVE LANDSCAPE (Page No. - 161)
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGIES
13.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE LIQUID BIOPSY MARKET
TABLE 135 OVERVIEW OF STRATEGIES DEPLOYED BY SOME LIQUID BIOPSY PRODUCT MANUFACTURING COMPANIES
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 35 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE LIQUID BIOPSY MARKET
13.4 MARKET SHARE ANALYSIS
FIGURE 36 LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER (2020)
TABLE 136 LIQUID BIOPSY MARKET: DEGREE OF COMPETITION
13.5 COMPANY EVALUATION QUADRANT
13.5.1 LIST OF EVALUATED VENDORS
13.5.2 STARS
13.5.3 EMERGING LEADERS
13.5.4 PERVASIVE PLAYERS
13.5.5 PARTICIPANTS
FIGURE 37 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
13.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020)
13.6.1 PROGRESSIVE COMPANIES
13.6.2 STARTING BLOCKS
13.6.3 RESPONSIVE COMPANIES
13.6.4 DYNAMIC COMPANIES
FIGURE 38 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020
13.7 COMPETITIVE BENCHMARKING
FIGURE 39 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE LIQUID BIOPSY MARKET
TABLE 137 COMPANY PRODUCT TYPE FOOTPRINT
TABLE 138 COMPANY GEOGRAPHICAL FOOTPRINT
13.8 COMPETITIVE SCENARIO
13.8.1 PRODUCT LAUNCHES AND REGULATORY APPROVALS
TABLE 139 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
13.8.2 DEALS
TABLE 140 KEY DEALS
13.8.3 LIQUID BIOPSY: OTHER DEVELOPMENTS
TABLE 141 OTHER KEY DEVELOPMENTS
14 COMPANY PROFILES (Page No. - 173)
14.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 QIAGEN N.V.
TABLE 142 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 40 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
14.1.2 F. HOFFMANN-LA ROCHE
TABLE 143 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
14.1.3 MYRIAD GENETICS, INC.
TABLE 144 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
FIGURE 42 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2020)
14.1.4 THERMO FISHER SCIENTIFIC INC.
TABLE 145 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)
14.1.5 GUARDANT HEALTH, INC.
TABLE 146 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
FIGURE 44 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2020)
14.1.6 BIO-RAD LABORATORIES
TABLE 147 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 45 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)
14.1.7 ILLUMINA, INC.
TABLE 148 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 46 ILLUMINA: COMPANY SNAPSHOT (2020)
14.1.8 EXACT SCIENCES
TABLE 149 EXACT SCIENCES: BUSINESS OVERVIEW
FIGURE 47 EXACT SCIENCES: COMPANY SNAPSHOT (2020)
14.1.9 SYSMEX INOSTICS (SUBSIDIARY OF SYSMEX CORPORATION)
TABLE 150 SYSMEX INOSTICS: BUSINESS OVERVIEW
FIGURE 48 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)
14.1.10 BIOCEPT, INC.
TABLE 151 BIOCEPT, INC.: BUSINESS OVERVIEW
FIGURE 49 BIOCEPT, INC.: COMPANY SNAPSHOT (2020)
14.1.11 MDX HEALTH
TABLE 152 MDX HEALTH: BUSINESS OVERVIEW
FIGURE 50 MDX HEALTH: COMPANY SNAPSHOT (2020)
14.2 OTHER PLAYERS
14.2.1 NEOGENOMICS, INC.
14.2.2 ANGLE PLC
14.2.3 EPIGENOMICS AG
14.2.4 MENARINI-SILICON BIOSYSTEMS
14.2.5 VORTEX BIOSCIENCES, INC.
14.2.6 EXOSOME DIAGNOSTICS, INC.
14.2.7 MEDGENOME INC.
14.2.8 AGENA BIOSCIENCE, INC.
14.2.9 PERSONAL GENOME DIAGNOSTICS, INC.
14.2.10 FREENOME HOLDINGS, INC.
14.2.11 STRAND LIFE SCIENCES
14.2.12 LUNGLIFE AI, INC.
14.2.13 LUCENE HEALTH INC.
14.2.14 ANPAC BIO-MEDICAL SCIENCE CO., LTD.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15 APPENDIX (Page No. - 224)
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 AVAILABLE CUSTOMIZATIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the liquid biopsy market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the liquid biopsy market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the liquid biopsy market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Global Liquid Biopsy Market Size: Top-Down Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, segment, and forecast the global liquid biopsy market by product & service, circulating biomarkers, technology, application, clinical application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall liquid biopsy market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to four regions, namely, North America, Europe, the Asia Pacific (APAC), and the Rest of the World (RoW)
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
- To track and analyze company developments such as product launches, regulatory approvals, expansions, agreements, partnerships, collaborations, and acquisitions in the liquid biopsy market
- To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Country Information
- Liquid biopsy market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa
Company Profiles
- Additional five company profiles of players operating in the liquid biopsy market.
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Liquid Biopsy Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Liquid Biopsy Market
What will be the global market value for Liquid Biopsy Market in 2029?
Which of the end user segment is expected to hold the major share of the global Liquid Biopsy Market?